Myeloma UK is launching a new research programme to continue support for patient-centric myeloma clinical trials in the UK, the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Programme (UKMRA-Myeloma UK-CARP). This initiative is part of an ambitious new strategy Myeloma UK recently published with a mission to make myeloma history. One of our key…
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
The National Institute of Health and Care Excellence (NICE) has approved the myeloma treatment lenalidomide (Revlimid®) and dexamethasone for use in treating newly diagnosed patients and patients at first relapse. The decision means that lenalidomide and dexamethasone will now be available on the NHS to patients in England and Wales who are not eligible for…
The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…
Myeloma is a relapsing-remitting blood cancer arising from the clonal expansion of abnormal plasma cells in the bone marrow. It is a difficult cancer to diagnose due to the vagueness of symptoms and rarity of the disease. This means myeloma patients experience some of the longest delays in diagnosis of all cancer patients. Myeloma UK…
This new treatment combination is being made available via the CDF on the NHS for the first time following a recommendation by the National Institute of Health and Care Excellence (NICE). This decision follows an earlier draft negative decision by NICE in July last year. Daratumumab, which is produced by the pharmaceutical company Janssen, belongs to a…
The IMWG present updated recommendations for the treatment of vertebral compression fractures in patients with myeloma by cement augmentation
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
The Myeloma Diagnosis Pathway is an easy to follow, quick reference tool to help GPs and other healthcare professionals recognise the signs and symptoms of myeloma. It provides information on which tests and investigations should be conducted before referral to a haematologist. It has been designed by Myeloma UK and reviewed by a working group…
